|
1.
|
Muller JM, Erasmi H, Stelzner M, et al:
Surgical therapy of oesophageal carcinoma. Br J Surg. 77:845–857.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Refaely Y and Krasna MJ: Multimodality
therapy for esophageal cancer. Surg Clin North Am. 82:729–746.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Walsh TN, Noonan N, Hollywood D, et al: A
comparison of multimodal therapy and surgery for esophageal
adenocarcinoma. N Engl J Med. 335:462–467. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Gebski V, Burmeister B, Smithers BM, et
al: Survival benefits from neoadjuvant chemoradiotherapy or
chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet
Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Tepper J, Krasna MJ, Niedzwiecki D, et al:
Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar
|
|
6.
|
Law S, Fok M, Chow S, et al: Pre-operative
chemotherapy versus surgical therapy alone for squamous cell
carcinoma of the esophagus: a prospective randomized trial. J
Thorac Cardiovasc Surg. 114:210–217. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Medical Research Council Oesophageal
Cancer Working Group: Surgical resection with or without
pre-operative chemotherapy in oesophageal cancer: a randomized
controlled trial. Lancet. 359:1727–1733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Yano M, Takachi K, Doki Y, et al:
Pre-operative chemotherapy for clinically node-positive patients
with squamous cell carcinoma of the esophagus. Dis Esophagus.
19:158–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
McMillan Dc, Canna K and McArdle CS:
Systemic inflammatory response predicts survival following curative
resection of colorectal cancer. Br J Surg. 90:215–219. 2003.
View Article : Google Scholar
|
|
10.
|
Pierce BL, Ballard-Barbash R, Bernstein L,
et al: Elevated biomarkers of inflammation are associated with
reduced survival among breast cancer patients. J Clin Oncol.
27:3437–3444. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kodama J, Miyagi Y, Seki N, et al: Serum
C-reactive protein as a prognostic factor in patients with
epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol.
82:107–110. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ishizuka M, Nagata H, Takagi K and Kubota
K: Influence of inflammation-based prognostic score on mortality of
patients undergoing chemotherapy for far advanced or recurrent
unresectable colorectal cancer. Ann Surg. 250:268–272. 2009.
View Article : Google Scholar
|
|
13.
|
Forrest LM, McMillan DC, McArdle CS, et
al: A prospective longitudinal study of performance status, an
inflammation-based score (GPS) and survival in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 92:1834–1836.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Al Murri AM, Bartlett JM, Canney PA, et
al: Evaluation of an inflammation-based prognostic score (GPS) in
patients with metastatic breast cancer. Br J Cancer. 94:227–230.
2006.PubMed/NCBI
|
|
15.
|
Nozoe T, Saeki H and Sugimachi K:
Significance of pre-operative elevation of serum C-reactive protein
as an indicator of prognosis in esophageal carcinoma. Am J Surg.
182:197–201. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Shimada H, Nabeya Y, Okazumi S, et al:
Elevation of pre-operative serum C-reactive protein level is
related to poor prognosis in esophageal squamous cell carcinoma. J
Surg Oncol. 83:248–252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ikeda M, Natsugoe S, Ueno S, et al:
Significant host- and tumor-related factors for predicting
prognosis in patients with esophageal carcinoma. Ann Surg.
238:197–202. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Zingg U, Forberger J, Rajcic B, et al:
Association of C-reactive protein levels and long-term survival
after neoadjuvant therapy and esophagectomy for esophageal cancer.
J Gastrointest Surg. 14:462–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Miyata H, Yoshioka A, Yamasaki M, et al:
Tumor budding in tumor invasive front predicts prognosis and
survival of patients with esophageal squamous cell carcinomas
receiving neoadjuvant chemotherapy. Cancer. 115:3324–3334. 2009.
View Article : Google Scholar
|
|
20.
|
Japanese Society for Esophageal Diseases:
Guidelines for the Clinical and Pathologic Studies on Carcinoma of
the Esophagus. 10th edition. Kanehara Syuppan; Tokyo: 2007
|
|
21.
|
Gomez D, Farid S, Malik HZ, et al:
Pre-operative neutrophil-to-lymphocyte ratio as a prognostic
predictor after curative resection for hepatocellular carcinoma.
World J Surg. 32:1757–1762. 2008. View Article : Google Scholar
|
|
22.
|
Walsh SR, Cook EJ, Goulder F, et al:
Neutrophil-lymphocyte ratio as a prognostic factor in colorectal
cancer. J Surg Oncol. 91:181–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Macciò A, Madeddu C, Massa D, et al:
Hemoglobin levels correlate with interleukin-6 levels in patients
with advanced untreated epithelial ovarian cancer: role of
inflammation in cancer-related anemia. Blood. 106:362–367.
2005.
|
|
24.
|
Buck I, Morceau F, Grigorakaki C, et al:
Linking anemia to inflammation and cancer: the crucial role of TNF
alpha. Biochem Pharmacol. 77:1572–1579. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Adamson JW: The anemia of
inflammation/malignancy: mechanisms and management. Hematology Am
Soc Hematol Educ Program. 2008:159–165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Gelin J, Moldawer LL, Lönnroth C, et al:
Role of endogenous tumor necrosis factor alpha and interleukin 1
for experimental tumor growth and the development of cancer
cachexia. Cancer Res. 51:415–421. 1991.PubMed/NCBI
|
|
27.
|
Heikkilä K, Ebrahim S and Lawlor DA: A
systematic review of the association between circulating
concentrations of C reactive protein and cancer. J Epidemiol
Community Health. 61:824–833. 2007.PubMed/NCBI
|
|
28.
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
McMillan DC, Watson WS, O'Gorman P, et al:
Albumin concentrations are primarily determined by the body cell
mass and the systemic inflammatory response in cancer patients with
weight loss. Nutr Cancer. 39:210–213. 2001. View Article : Google Scholar
|
|
30.
|
Argilés JM, Busquets S and López-Soriano
FJ: Cytokines as mediators and targets for cancer cachexia. Cancer
Treat Res. 130:199–217. 2006.
|
|
31.
|
Neal CP, Mann CD, Sutton CD, et al:
Evaluation of the prognostic value of systemic inflammation and
socioeconomic deprivation in patients with resectable colorectal
liver metastases. Eur J Cancer. 45:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Wang CY, Hsieh MJ, Chiu YC, et al: Higher
serum C-reactive protein concentration and hypoalbuminemia are poor
prognostic indicators in patients with esophageal cancer undergoing
radiotherapy. Radiother Oncol. 92:270–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Di Fiore F, Lecleire S, Pop D, et al:
Baseline nutritional status is predictive of response to treatment
and survival in patients treated by definitive chemoradiotherapy
for a locally advanced esophageal cancer. Am J Gastroenterol.
102:2557–2563. 2007.PubMed/NCBI
|
|
34.
|
Crumley AB, McMillan DC, McKernan M, et
al: Evaluation of an inflammation-based prognostic score in
patients with inoperable gastro-oesophageal cancer. Br J Cancer.
94:637–641. 2006.PubMed/NCBI
|
|
35.
|
Kobayashi T, Teruya M, Kishiki T, et al:
Inflammation-based prognostic score, prior to neoadjuvant
chemoradiotherapy, predicts postoperative outcome in patients with
esophageal squamous cell carcinoma. Surgery. 144:729–735. 2008.
View Article : Google Scholar
|
|
36.
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9:2122007. View
Article : Google Scholar
|
|
37.
|
Ulrich CM, Bigler J and Potter JD:
Non-steroidal anti-inflammatory drugs for cancer prevention:
promise, perils and pharmacogenetics. Nat Rev Cancer. 6:130–140.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Macciò A, Lai P, Santona MC, et al: High
serum levels of soluble IL-2 receptor, cytokines, and C reactive
protein correlate with impairment of T cell response in patients
with advanced epithelial ovarian cancer. Gynecol Oncol. 69:248–252.
1998.PubMed/NCBI
|
|
39.
|
Canna K, McArdle PA, McMillan DC, et al:
The relationship between tumour T-lymphocyte infiltration, the
systemic inflammatory response and survival in patients undergoing
curative resection for colorectal cancer. Br J Cancer. 92:651–654.
2005. View Article : Google Scholar
|
|
40.
|
Moyes LH, Leitch EF, McKee RF, et al:
Pre-operative systemic inflammation predicts postoperative
infectious complications in patients undergoing curative resection
for colorectal cancer. Br J Cancer. 100:1236–1239. 2009. View Article : Google Scholar
|
|
41.
|
Lerut T, Moons J, Coosemans W, et al:
Postoperative complications after transthoracic esophagectomy for
cancer of the esophagus and gastroesophageal junction are
correlated with early cancer recurrence: role of systematic grading
of complications using the modified Clavien classification. Ann
Surg. 250:798–807. 2009. View Article : Google Scholar
|
|
42.
|
Lagarde SM, de Boer JD, ten Kate FJ, et
al: Postoperative complications after esophagectomy for
adenocarcinoma of the esophagus are related to timing of death due
to recurrence. Ann Surg. 247:71–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
